Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
18:21:04 EDT Thu 02 May 2024
Enter Symbol
or Name
USA
CA



News for U:OPSSF from 2023-05-03 to 2024-05-02 - 14 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2023-12-12 06:00U:OPSSFNews ReleaseHAEMONETICS COMPLETES ACQUISITION OF OPSENS
2023-12-08 07:00U:OPSSFNews ReleaseOPSENS RECEIVES FINAL ORDER FOR ARRANGEMENT WITH HAEMONETICS
2023-12-01 13:48U:OPSSFNews ReleaseOPSENS' SHAREHOLDERS APPROVE ARRANGEMENT WITH HAEMONETICS
2023-11-28 07:00U:OPSSFNews ReleaseOPSENS OBTAINS REGULATORY CLEARANCE OF ARRANGEMENT IN THE UNITED STATES AND CANADA; REGULATORY APPROVALS CONDITION SATISFIED
2023-11-22 11:00U:OPSSFNews ReleaseOPSENS ANNOUNCES FOURTH QUARTER AND FISCAL YEAR 2023 FINANCIAL RESULTS
2023-11-13 08:00U:OPSSFNews ReleaseINDEPENDENT PROXY ADVISORY FIRM ISS RECOMMENDS SHAREHOLDERS VOTE "FOR" OPSENS INC. PLAN OF ARRANGEMENT WITH HAEMONETICS CORPORATION
2023-11-02 07:00U:OPSSFNews ReleaseOPSENS RECEIVES INTERIM ORDER AND FILES MANAGEMENT INFORMATION CIRCULAR IN CONNECTION WITH SPECIAL MEETING OF SHAREHOLDERS
2023-10-23 13:22U:OPSSFNews ReleaseOPSENS ANNOUNCES THE POSITIVE CLINICAL RESULTS FROM THE SAFE-TAVI STUDY WITH SAVVYWIRE IN EUROPE
2023-10-17 09:00U:OPSSFNews ReleaseOpSens to Participate in the Transcatheter Cardiovascular Therapeutics Conference (TCT) in San Francisco October 23 - 26, 2023
2023-10-10 06:00U:OPSSFNews ReleaseOPSENS SIGNS DEFINITIVE AGREEMENT FOR ITS ACQUISITION BY HAEMONETICS
2023-10-10 06:00U:OPSSFNews ReleaseHaemonetics Corporation Announces Definitive Agreement to Acquire OpSens, Inc.
2023-07-13 07:00U:OPSSFNews ReleaseOPSENS ANNOUNCES A THIRD CONSECUTIVE QUARTER OF RECORD REVENUES FOR THIRD QUARTER FISCAL 2023
2023-07-06 09:00U:OPSSFNews ReleaseOPSENS TO HOST THIRD QUARTER FISCAL YEAR 2023 FINANCIAL RESULTS CONFERENCE CALL ON THURSDAY JULY 13, 2023
2023-05-10 07:00U:OPSSFNews ReleaseOPSENS ANNOUNCES INCLUSION OF SAVVYWIRE ™ IN COMPLETE TAVR STUDY